NEW YORK (GenomeWeb News) – Metabolon announced today that it is collaborating with Harvard-Partners Center for Genetics and Genomics on developing a new test for warfarin dosing.
The alliance is aimed at determining whether a patient’s metabolomic profile will increase the likelihood of correctly dosing wafarin.
HPCGG is a joint effort between Harvard Medical School and Partners Healthcare medical system in the Boston area.
Partners is conducting a prospective study using genetic testing in an attempt to find the optimal warfarin dose for individual patients. It expects to complete sample collection from that study early this coming summer, after which Metabolon will conduct metabolomic analysis. HPCGG and Metabolon expect to report results from their collaboration in a peer-reviewed publication.
“Metabolon’s biomarker discovery platform gives us the opportunity to find biochemical markers that along with genetic variations might help characterize the differences between patients’ metabolism of warfarin,” Raju Kucherlapati, director of HPCGG, said in a statement.
Over the past couple of years, many firms have embarked on development of molecular diagnostic tests to guide warfarin dosing. Thus far, two firms — Nanosphere and Autogenomics — have gained US Food and Drug Administration clearance to market their tests.
Clearance of their tests followed the FDA’s update of labeling for warfarin, which explains how a person’s genetics may impact their response to the anticoagulant and “highlights the opportunity for healthcare providers to use genetic tests to improve their initial estimate of what is a reasonable warfarin dose for individual patients,” the FDA said in a statement at the time.
In addition to the collaboration, Partners HealthCare investigators gained preferred access to Metabolon’s global biochemical profiling platform, which extracts, identifies, and quantitates hundreds of small molecule biochemicals in a given biological sample.
Financial and other terms of the alliance were not disclosed.